These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 22387337

  • 1. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption.
    Beig A, Miller JM, Dahan A.
    Eur J Pharm Biopharm; 2012 Jun; 81(2):386-91. PubMed ID: 22387337
    [Abstract] [Full Text] [Related]

  • 2. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
    Miller JM, Beig A, Carr RA, Webster GK, Dahan A.
    Mol Pharm; 2012 Mar 05; 9(3):581-90. PubMed ID: 22280478
    [Abstract] [Full Text] [Related]

  • 3. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation.
    Miller JM, Beig A, Krieg BJ, Carr RA, Borchardt TB, Amidon GE, Amidon GL, Dahan A.
    Mol Pharm; 2011 Oct 03; 8(5):1848-56. PubMed ID: 21800883
    [Abstract] [Full Text] [Related]

  • 4. Striking the Optimal Solubility-Permeability Balance in Oral Formulation Development for Lipophilic Drugs: Maximizing Carbamazepine Blood Levels.
    Beig A, Miller JM, Lindley D, Dahan A.
    Mol Pharm; 2017 Jan 03; 14(1):319-327. PubMed ID: 27981848
    [Abstract] [Full Text] [Related]

  • 5. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
    Miller JM, Beig A, Carr RA, Spence JK, Dahan A.
    Mol Pharm; 2012 Jul 02; 9(7):2009-16. PubMed ID: 22632106
    [Abstract] [Full Text] [Related]

  • 6. Head-To-Head Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent Solubility-Permeability Interplay.
    Beig A, Miller JM, Lindley D, Carr RA, Zocharski P, Agbaria R, Dahan A.
    J Pharm Sci; 2015 Sep 02; 104(9):2941-7. PubMed ID: 25989509
    [Abstract] [Full Text] [Related]

  • 7. The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with a cosolvent-based formulation.
    Fine-Shamir N, Beig A, Miller JM, Dahan A.
    Int J Pharm; 2020 May 30; 582():119307. PubMed ID: 32276090
    [Abstract] [Full Text] [Related]

  • 8. Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation.
    Miller JM, Dahan A.
    Int J Pharm; 2012 Jul 01; 430(1-2):388-91. PubMed ID: 22465550
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Methacrylate-Copolymer Eudragit EPO as a Solubility-Enabling Excipient for Anionic Drugs: Investigation of Drug Solubility, Intestinal Permeability, and Their Interplay.
    Fine-Shamir N, Dahan A.
    Mol Pharm; 2019 Jul 01; 16(7):2884-2891. PubMed ID: 31120762
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations.
    Beig A, Agbaria R, Dahan A.
    PLoS One; 2013 Jul 01; 8(7):e68237. PubMed ID: 23874557
    [Abstract] [Full Text] [Related]

  • 14. Ethanol-based solubility-enabling oral drug formulation development: Accounting for the solubility-permeability interplay.
    Fine-Shamir N, Dahan A.
    Int J Pharm; 2024 Mar 25; 653():123893. PubMed ID: 38346600
    [Abstract] [Full Text] [Related]

  • 15. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone.
    Dahan A, Miller JM, Hoffman A, Amidon GE, Amidon GL.
    J Pharm Sci; 2010 Jun 25; 99(6):2739-49. PubMed ID: 20039391
    [Abstract] [Full Text] [Related]

  • 16. Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract.
    Masaoka Y, Tanaka Y, Kataoka M, Sakuma S, Yamashita S.
    Eur J Pharm Sci; 2006 Nov 25; 29(3-4):240-50. PubMed ID: 16876987
    [Abstract] [Full Text] [Related]

  • 17. The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off.
    Beig A, Miller JM, Dahan A.
    Eur J Pharm Biopharm; 2013 Nov 25; 85(3 Pt B):1293-9. PubMed ID: 23770429
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.